Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexofenadine/Pseudoephedrine Combination in Seasonal Allergic Rhinitis
NCT01306721Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2011
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pseudoephedrine in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Sanofi. Primary endpoint: Changes in the nasal congestion score at 2 weeks. Started Feb 2011; status: completed.
02
Drugs
pseudoephedrine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT01306721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01306721.